Tweet
Tweet
The Top Performing Stocks Of 2015by Bespoke InvestBelow is a list of the top performing stocks in the Russell 3,000 year-to-date. Of the 3,000 stocks in the index, 18 are up more than 100%. The best performer in the index is Retrophin (RTRX), which is up 161%. In recent years past, there have been at least a couple stocks up […]
View original post here:
Biotech Stocks Attracting Some Extra Attention – Seattle Genetics (SGEN … – Wall Street Observer
See which stocks are being affected by Social Media
[…]
Some decisions in life deserve serious, thoughtful contemplation.Other times, you have to make a split-second decision and live with the consequences.Picking companies to pitch in hedge fund and private equity case studies falls somewhere in the middle.If you already have a few companies in mind, you need to decide on one quickly – but if you have no clue where […]
Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of ShortfallSYDNEY /PRNewswire/ — US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the non-renounceable pro-rata rights issue entitlement announced on 21 April 2015 (Rights Issue) was completed successfully.The Rights Issue offered up to 58,971,207 new shares at an issue price of $0.30 per share and […]
“The watch-out level of the week is placed at 8270, stands convincingly violated, without much effort. The next support in order is at 8100-8080, which corresponds to the closing low of May 2015,” GEPL Capital said in a report.”Upside resistance overhangs are established now at 8270, 8333 (200 DMA simple), 8422 (50 simple DMA) & 8550(100 simple DMA),” he adds.
I have to agree with this article.
At a recent International Monetary Fund event in Washington, D.C., Federal Reserve Chair Janet Yellen opined about the “potential dangers” posed by “quite high” stock market valuations. This was not her first market prognostication. In July 2014 she singled out biotech and social-media stocks as having “substantially stretched” valuations. Such comments are ill considered […]
This maddening sideways chop continues and the best “risk on” sector, biotech, looks heavy and tired. The leaders in this space are heavy, AMGN has a bearish head and shoulder pattern going on and CELG and BIIB just cant stop stepping on their feet. GILD acts the best of the big four biotechs. The other biggie, REGN, continues to hang […]
Stocks continued their directionless ways Tuesday, with indexes wiggling around the unchanged mark for the day. Biotechs showed some weakness, but not much else could be gleaned from the day. My leaders list hasn’t found any new names, but also hasn’t been forced out of any. It hasn’t moved more than 1% up or down for weeks. GWPH was the […]
From:
Is Endo Pharmaceuticals (ENDP) Passing The End Point? June 02, 2015 at 12:32 PM | written by Greg Schnell
See which stocks are being affected by Social Media
[…]
Biotech Indices Can’t Break Through Triple Top
IBB at $365, XBI at $239
Red and green day
Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers.
First look at Rayno Biopharmaceutical Portfolio stocks:
Our big mover […]
